Tsai Tsung-You, Chiang Pin-Chun, Yap Wing-Keen, Huang Yenlin, See Anna, Hung Shao-Yu, Lu Chuieng-Yi, Lin Chien-Yu, Chang Tung-Chieh Joseph, Kao Huang-Kai, Chang Kai-Ping
Department of Otolaryngology-Head and Neck Surgery Chang Gung Memorial Hospital Taoyuan Taiwan.
College of Medicine Chang Gung University Taoyuan Taiwan.
Laryngoscope Investig Otolaryngol. 2024 May 15;9(3):e1260. doi: 10.1002/lio2.1260. eCollection 2024 Jun.
The aim of this meta-analysis is to evaluate the potential benefits of postoperative radiotherapy (PORT) in patients with pN1 oral cavity squamous cell carcinoma.
A literature search through major databases was conducted until January 2023. The adjusted hazard ratio (aHR) or risk ratio (RR) with 95% confidence intervals (CIs) of different survival outcomes were extracted and pooled.
Ten studies published between 2005 and 2022, with a pooled patient population of 2888, were included in this meta-analysis. Due to differences in study design and reported outcomes, the studies were categorized into distinct groups. In pN1 patients without extranodal extension (ENE), PORT was associated with a significant improvement in overall survival (OS) (aHR 0.76, 95% CI: 0.61-0.94). In pN1 patients without ENE and positive margins, PORT improved OS (aHR 0.71, 95% CI: 0.56-0.89) and was associated with a lower regional recurrence rate (RR 0.35, 95% CI: 0.15-0.83). However, in pN1 patients without ENE, positive margins, perineural invasion, and lymphovascular invasion, there were no significant differences observed between the PORT and observation groups in either 5-year OS (RR 0.48, 95% CI: 0.07-3.41) or 5-year disease-free survival (RR 0.37, 95% CI: 0.07-2.06).
The current study demonstrated that PORT has the potential to improve OS in pN1 disease. However, the decision of whether to administer PORT still hinges on diverse clinical scenarios, and additional research is necessary to furnish a more conclusive resolution.
本荟萃分析旨在评估术后放疗(PORT)对pN1期口腔鳞状细胞癌患者的潜在益处。
通过主要数据库进行文献检索,截止至2023年1月。提取并汇总不同生存结局的调整后风险比(aHR)或风险比(RR)及95%置信区间(CI)。
本荟萃分析纳入了2005年至2022年间发表的10项研究,汇总患者群体为2888例。由于研究设计和报告结局存在差异,这些研究被分为不同组。在无结外侵犯(ENE)的pN1患者中,PORT与总生存期(OS)显著改善相关(aHR 0.76,95%CI:0.61 - 0.94)。在无ENE且切缘阳性的pN1患者中,PORT改善了OS(aHR 0.71,95%CI:0.56 - 0.89),并与较低的区域复发率相关(RR 0.35,95%CI:0.15 - 0.83)。然而,在无ENE、切缘阳性、神经周围侵犯和脉管侵犯的pN1患者中,PORT组与观察组在5年OS(RR 0.48,95%CI:0.07 - 3.41)或5年无病生存期(RR 0.37,95%CI:0.07 - 2.06)方面均未观察到显著差异。
当前研究表明,PORT有可能改善pN1期疾病的OS。然而,是否给予PORT的决定仍取决于多种临床情况,需要更多研究以提供更具决定性的解决方案。
2级。